-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-IN-7
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2570461-66-2.gif)
| Category | SARS-CoV |
| CAS | 2570461-66-2 |
| Description | SARS-CoV-2-IN-7 inhibits viral replication in SARS-CoV-2-infected Vero E6 cells, which has the potential for COVID-19 research. |
Product Information
| Synonyms | SARS-CoV-2-IN-7|SCHEMBL10501884|HY-141841|CS-0254871 |
| IUPAC Name | 2-[3-(trifluoromethyl)phenyl]-1,2-benzoselenazol-3-one |
| Molecular Weight | 342.17 |
| Molecular Formula | C14H8F3NOSe |
| Canonical SMILES | C1=CC=C2C(=C1)C(=O)N([Se]2)C3=CC=CC(=C3)C(F)(F)F |
| InChI | InChI=1S/C14H8F3NOSe/c15-14(16,17)9-4-3-5-10(8-9)18-13(19)11-6-1-2-7-12(11)20-18/h1-8H |
| InChIKey | AUNYFNONXIUSKI-UHFFFAOYSA-N |
| Purity | 98% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Light yellow to orange (Solid) |
| Storage | Store at 2-8°C |
| Complexity | 387 |
| Exact Mass | 342.97232 |
| Target | SARS-CoV |
